

Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

2012 ASCO-GI Publication Schedule / Conference Call Details

Ladies and Gentlemen,

Findings from the Phase III CORRECT study of Regorafenib in patients with metastatic colorectal cancer (mCRC) will be presented at the American Society of Clinical Oncology, Gastrointestinal Cancers Symposium (ASCO-GI) in San Francisco, USA, on January 21, 2012, 2:30 p.m. – 4:00 p.m. PST. We cordially invite investors and analysts to participate in our conference call on this occasion.

The schedule is as follows:

After congress embargo lift	**Press release on Regorafenib data presented at the 2012 ASCO-GI congress** (after lift of congress embargo, currently expected on January 17 at 6:00 p.m. EST)
Monday January 23, 2012	**Internet address for all information material and webcast:** www.investor.bayer.com / www.investor.bayer.de
12:30 p.m. CET	**Investor Conference Call to discuss findings from the Phase III CORRECT study of Regorafenib in mCRC presented at ASCO-GI** with Dr. Kemal Malik, Head of Global Development at Bayer Healthcare Pharmaceuticals, Dr. Jörg Möller, Head of Global Clinical Development and Dr. Alexander Rosar, Head of Investor Relations
	Dial-in Numbers **International: +44 203 059 8128** **UK: 0203 059 8128** **US: 1 855 272 3513** **Germany: 069 566 036 000** If you are unable to participate in the conference, a recording will be available for access by touch tone telephone until January 26, 2012. A live audio broadcast (English only) will be available on the internet.
	Replay Dial-in Numbers **International: +44 121 260 4861, Passcode: 52001#** **UK: 0121 260 4861, Passcode: 52001#** **US: 646 200 5850, Passcode: 52001#** **Germany: 069 710 488 70, Passcode: 52001#**
04:00 p.m. CET	On-demand version of the conference call webcast available on the internet.

CET = Central European Time = Greenwich Mean Time (GMT) +1 hour; EST = Eastern Standard Time = Greenwich Mean Time (GMT) -5 hours; PST = Pacific Standard Time = Greenwich Mean Time (GMT) -8 hours

Best regards,
Bayer Investor Relations